Versant Capital Management’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.23K Sell
19
-9
-32% -$655 ﹤0.01% 2683
2026
Q2
$2.28K Hold
28
– – ﹤0.01% 2546
2026
Q1
$1.91K Buy
28
+12
+75% +$850 ﹤0.01% 2575
2025
Q4
$1.22K Hold
16
– – ﹤0.01% 2510
2025
Q3
$982 Hold
16
– – ﹤0.01% 2512
2025
Q2
$781 Buy
+16
New +$760 ﹤0.01% 2515
2023
Q3
– Sell
-14
Closed -$569 – 2030
2023
Q2
$569 Buy
+14
New +$685 ﹤0.01% 1805
2021
Q3
– Sell
-17
Closed -$1K – 1562
2021
Q2
$1K Buy
+17
New +$728 ﹤0.01% 1345

Other funds holding PTCT

Versant Capital Management's PTCT Position: Q3 2026 in Review

Versant Capital Management reduced its PTC Therapeutics (PTCT) stake by 32% in Q3 2026, selling an estimated $655 and leaving 19 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

Versant Capital Management first reported a position in PTCT in Q2 2021 and has held it in 8 quarters since. The position peaked at $2.28K in Q2 2026. 359 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • Versant Capital Management held 19 shares of PTC Therapeutics worth $1.23K as of Q3 2026.
  • Versant Capital Management sold 9 PTC Therapeutics shares in Q3 2026, an estimated $655.
  • PTC Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2683 holding.
  • Versant Capital Management first reported a position in PTC Therapeutics in Q2 2021 and has held it in 8 quarters since.
  • Versant Capital Management's PTC Therapeutics position peaked at $2.28K in Q2 2026.
  • 359 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.